نتایج جستجو برای: idarubicin

تعداد نتایج: 767  

2016
Tomoyoshi Komiyama Atsushi Ogura Takatsugu Hirokawa Miao Zhijing Hiroshi Kamiguchi Satomi Asai Hayato Miyachi Hiroyuki Kobayashi

Gene alterations are a well-established mechanism leading to drug resistance in acute leukemia cells. A full understanding of the mechanisms of drug resistance in these cells will facilitate more effective chemotherapy. In this study, we investigated the mechanism(s) of drug resistance in the human acute leukemia cell line MOLT-3 and its idarubicin-resistant derivative MOLT-3/IDR through comple...

Journal: :Blood 2005
Anna Maria Testi Andrea Biondi Francesco Lo Coco Maria Luisa Moleti Fiorina Giona Marco Vignetti Giuseppe Menna Franco Locatelli Andrea Pession Elena Barisone Giulio De Rossi Daniela Diverio Concetta Micalizzi Maurizio Aricò Giuseppe Basso Robert Foa Franco Mandelli

The role of all-trans retinoic acid (ATRA) in pediatric acute promyelocytic leukemia (APL) is the topic of several ongoing studies. The results of the Italian pediatric experience with the multicentric Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA)-Italian Pediatric Hematology and Oncology Group (AIEOP) "AIDA" (ATRA and idarubicin) trial are presented. Of the 983 patients wit...

2011
Olivier LaRochelle Sarah Bertoli François Vergez Jean-Emmanuel Sarry Véronique Mansat-De Mas Sophie Dobbelstein Nicole Dastugue Anne-Claire Strzelecki Cindy Cavelier Laurent Creancier Arnaud Pillon Anna Kruczynski Cécile Demur Audrey Sarry Françoise Huguet Anne Huynh Christian Récher Eric Delabesse

Mutations in DNMT3A encoding DNA methyltransferase 3A were recently described in patients with acute myeloid leukemia. To assess their prognostic significance, we determined the mutational status of DNMT3A exon 23 in 288 patients with AML excluding acute promyelocytic leukemia, aged from 18 to 65 years and treated in Toulouse University Hospital. A mutation was detected in 39 patients (13.5%). ...

2013
Rong Hu Jia Li Yanping Hu Jihong Zhang Miao Miao Ke Zhu Aijun Liao Wei Yang Zhuogang Liu

Patient: Female, 55 Final Diagnosis: Acute leukemia Symptoms: Thrombocytosis Medication: Idarubicin HCl (Zavedos), Pfizer Clinical Procedure: - Specialty: Hematology. OBJECTIVE Adverse effect of drug therapy. BACKGROUND Thrombocytosis is usually seen in myeloproliferative disorders (MPD) and seldo...

Journal: :Haematologica 2009
Pau Montesinos Joaquín Díaz-Mediavilla Guillermo Debén Virginia Prates Mar Tormo Vicente Rubio Inmaculada Pérez Isolda Fernández Maricruz Viguria Chelo Rayón José González Javier de la Serna Jordi Esteve Juan M Bergua Concha Rivas Marcos González Jose D González Silvia Negri Salut Brunet Bob Lowenberg Miguel A Sanz

BACKGROUND The prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established and remain a controversial matter. DESIGN AND METHODS Between 1996 and 2005, 739 patients with newly diagnosed acute promyelocytic leukemia enrolled in two consecutive trials (PETHEMA LPA96 and LPA99) received induction therapy with all-tra...

1999
Robert St. Amant

Over the past fteen years a variety of interactive IDA systems have been developed to support strategic reasoning for data analysis. We present an AI framework, hierarchical task network planning, that provides a unifying view of these e orts. We describe a taxonomy of strategic approaches to IDA, based on the planning framework, and discuss the strengths and weaknesses associated with each app...

Journal: :Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2007
Ioannis D Venizelos Ioannis Klonizakis Efthimia Vlahaki Styliani Haralambidou Zoi Tatsiou Elissavet Ioannidou

Acute myeloid leukemia (AML) is a morphologically diverse group of hematopoietic malignancies characterized by proliferation of immature cells that arise in the myeloid progenitor cells of the bone marrow. It shows cutaneous lesions relatively rarely. The most common cutaneous manifestation is the appearance of one or several tumors. An association of AML with skin involvement and trisomy 8 has...

Journal: :Haematologica 1996
P L Zinzani M Bendandi F Gherlinzoni E Merla A Gozzetti S Tura

Fludarabine (FLU) is a new antimetabolite chemotherapeutic agent with promising activity in lymphoproliferative disorders and, in particular, in low-grade non-Hodgkin's lymphoma (LG-NHL). Recently, a few reports have described interesting results using FLU in polychemotherapy regimens. In order to evaluate FLU in combination with other antineoplastic agents, we used a combination of FLU and ida...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید